DDInter93 DDInter178
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Anagrelide {u} (Compound) treats {v} (Disease) hematologic cancer
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
Anagrelide {u} (Compound) upregulates {v} (Gene) HMG20B
Anagrelide {u} (Compound) is included by {v} (Pharmacologic Class) Phosphodiesterase 3 Inhibitors
Anagrelide {u} (Compound) downregulates {v} (Gene) TM9SF2
Anagrelide {u} (Compound) causes {v} (Side Effect) Distress gastrointestinal
Anagrelide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milrinone
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Vorapaxar
Anagrelide (Compound) treats hematologic cancer (Disease)
Anagrelide (Compound) binds CYP1A2 (Gene)
Anagrelide (Compound) upregulates HMG20B (Gene)
Anagrelide (Compound) is included by Phosphodiesterase 3 Inhibitors (Pharmacologic Class)
Anagrelide (Compound) downregulates TM9SF2 (Gene)
Anagrelide (Compound) causes Distress gastrointestinal (Side Effect)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Capsicum
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Milrinone
Anagrelide may lead to a major life threatening interaction when taken with Vorapaxar